Hims & Hers Health has outperformed the market over the past 5 years by 17.4% on an annualized basis, producing an average annual return of 28.89%. This performance highlights the impact of compounded returns on investor wealth over time. The company currently commands a market capitalization of $8.66 billion.

Investment Growth Analysis

The significant appreciation in stock price translates to substantial growth for initial investors. If an individual had purchased $100 worth of Hims & Hers Health stock 5 years ago, that investment would be valued at $355.78 today. This calculation is based on a current share price of $37.41.

Key Performance Metrics

The data underscores the potential for long-term capital appreciation through consistent market outperformance.

Hims & Hers Health Inc shares rose on Wednesday after BofA Securities and Canaccord Genuity raised their price targets to $36 and $40 respectively, citing accelerating sales growth and a strategic shift toward branded weight-loss drugs. The revised targets reflect increased confidence in the NYSE-listed company's commercial momentum, even as regulatory scrutiny on peptide compounding intensifies ahead of a key FDA advisory committee meeting.

Canaccord Genuity analyst Maria Ripps maintained a Buy rating and increased the price target to $40 from $32. Ripps highlighted that the company's transition away from compounded weight loss drugs toward branded alternatives is gaining traction, noting that a Novo Nordisk executive recently described Hims as one of the pharmaceutical giant's most "voluminous" telehealth partners. Sales trends improved throughout the second quarter, with adjusted year-over-year growth accelerating from mid- to high-single digits in April to high-teens growth by June. The company launched generic semaglutide for Canadian customers in late May and completed its Eucalyptus acquisition in early June.

BofA Securities analyst Allen Lutz maintained a Neutral rating and raised the price target to $36 from $25. Lutz focused on the FDA's recommendation against adding seven peptides to the 503A Bulk List, noting that the agency's concerns regarding limited clinical evidence and unresolved safety questions present a potential headwind. The FDA released briefing materials ahead of Pharmacy Compounding Advisory Committee (PCAC) meetings scheduled for July 23 to 24. Lutz indicated that the briefing materials suggest the PCAC "has an uphill battle" to shift the FDA's stance, which could narrow the legal pathway for broad peptide compounding.

Despite the regulatory uncertainty, Lutz acknowledged that peptides represent a large addressable market and viewed the FDA's move to remove various wellness peptides from the Category 2 restricted list as a positive development. Hims shares gained roughly 67% during the second quarter.

Technical indicators suggest the stock is in a strong short-term uptrend. Hims & Hers trades 20.4% above its 20-day simple moving average of $31.08 and 32.6% above its 50-day simple moving average of $28.22. The MACD is above its signal line with a positive histogram, indicating strengthened buying pressure. However, the 50-day moving average remains below the 200-day moving average following a death cross in December 2025, signaling that the broader trend is still in a rebuilding phase. Key resistance is identified at $41.00, while support sits at $36.00.